Can a Patient on Qulipta (Atogepant) Also Use Ubrelvy (Ubrogepant) as Needed?
Yes, a patient taking Qulipta (atogepant) for migraine prevention can safely use Ubrelvy (ubrogepant) as needed for acute breakthrough migraine attacks. 1, 2
Evidence Supporting Concomitant Use
The combination of atogepant and ubrogepant has been specifically studied and proven safe in clinical trials. 1, 2
A phase Ib drug-drug interaction study demonstrated that co-administration of ubrogepant with atogepant resulted in only a 19% increase in ubrogepant exposure and a 26% increase in maximum plasma concentration—changes that were not clinically meaningful. 1
The TANDEM study (phase 4, open-label trial) evaluated 218 participants taking atogepant 60 mg daily for prevention while using ubrogepant 100 mg as needed for breakthrough attacks over 12 weeks. 2
Participants in the TANDEM study used ubrogepant an average of 6.6 days over the 12-week period, with no increase in adverse events related to the number of ubrogepant doses taken. 2
Treatment-emergent adverse events occurred in 43.1% of participants during the combination period, with the most common being COVID-19 (3.2%), fatigue (1.4%), and nausea (0.9%)—consistent with the known safety profiles of each drug used alone. 2
Only 9.9% of participants discontinued treatment due to adverse events during the entire study period, and no new safety signals were identified. 2
Practical Implementation
Ubrogepant should be used according to standard acute migraine treatment guidelines while on atogepant:
Use ubrogepant 50-100 mg at the onset of a breakthrough migraine attack. 3, 2
A second dose of ubrogepant may be taken if the headache does not resolve within 2-24 hours after the initial dose. 2
Limit ubrogepant use to no more than 8 migraine attacks per 30-day period to prevent medication-overuse headache. 4
Restrict all acute migraine medications (including ubrogepant) to ≤2 days per week (≤10 days per month) to avoid medication-overuse headache, which can paradoxically increase headache frequency. 5, 4
Clinical Context
This combination addresses a common clinical scenario: patients on preventive therapy still experience breakthrough attacks requiring acute treatment. 2
Atogepant reduces migraine frequency but does not eliminate all attacks. 5
Having ubrogepant available as an acute treatment provides patients with a CGRP-targeted option that is mechanistically compatible with their preventive therapy. 1, 2
Both medications are oral CGRP receptor antagonists, but atogepant is dosed daily for prevention while ubrogepant is used intermittently for acute attacks. 1, 2
Alternative Acute Options
If ubrogepant is unavailable or contraindicated, other acute treatments remain appropriate:
NSAIDs (ibuprofen 400-800 mg, naproxen 500-825 mg) for mild-to-moderate breakthrough attacks. 4
Triptans (sumatriptan 50-100 mg, rizatriptan 10 mg) for moderate-to-severe attacks, provided no cardiovascular contraindications exist. 4
Combination therapy (triptan + NSAID) provides superior efficacy compared to either agent alone. 4
Critical Frequency Limitation
Regardless of which acute medication is chosen, the ≤2 days per week limit is non-negotiable. 5, 4
If breakthrough attacks require acute treatment more than twice weekly despite atogepant, the preventive regimen should be reassessed and potentially escalated. 5
Frequent acute medication use can lead to medication-overuse headache, which sustains chronic migraine and reduces preventive therapy effectiveness. 5, 4